| Angiogenesis and VEGF in Cancer | Lifetime | 32 | JP 1 | 99.70 |
| Cardiovascular Disease and Adiposity | Lifetime | 106 | JP 5 | 99.35 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 126 | JP 8 | 99.31 |
| Mesenchymal stem cell research | Lifetime | 159 | JP 11 | 99.03 |
| Nitric Oxide and Endothelin Effects | Lifetime | 200 | JP 10 | 99.05 |
| Peripheral Artery Disease Management | Lifetime | 157 | JP 1 | 98.74 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 516 | JP 17 | 98.59 |
| Cardiovascular Function and Risk Factors | Lifetime | 495 | JP 6 | 99.10 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 450 | JP 11 | 98.87 |
| Lymphatic System and Diseases | Lifetime | 77 | JP 4 | 97.58 |
| Cardiac Arrhythmias and Treatments | Lifetime | 555 | JP 17 | 98.55 |
| Cardiac Imaging and Diagnostics | Lifetime | 807 | JP 13 | 98.79 |
| Coronary Interventions and Diagnostics | Lifetime | 426 | JP 6 | 98.75 |
| Cell Adhesion Molecules Research | Lifetime | 766 | JP 32 | 97.81 |
| Heart Failure Treatment and Management | Lifetime | 535 | JP 20 | 98.04 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 481 | JP 25 | 96.90 |
| Renin-Angiotensin System Studies | Lifetime | 305 | JP 35 | 97.03 |
| Cardiac pacing and defibrillation studies | Lifetime | 933 | JP 16 | 97.38 |
| Cardiovascular Health and Disease Prevention | Lifetime | 768 | JP 51 | 96.80 |
| Cardiac Ischemia and Reperfusion | Lifetime | 678 | JP 41 | 96.16 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 644 | JP 35 | 96.42 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 814 | JP 19 | 96.66 |
| Cardiovascular Issues in Pregnancy | Lifetime | 532 | JP 19 | 96.14 |
| Congenital heart defects research | Lifetime | 718 | JP 46 | 95.13 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | Lifetime | 451 | JP 40 | 91.91 |
| Biomarkers in Disease Mechanisms | Lifetime | 435 | JP 38 | 88.06 |
| Apelin-related biomedical research | Lifetime | 657 | JP 57 | 87.40 |
| Aortic Thrombus and Embolism | Lifetime | 983 | JP 178 | 58.40 |
| Heart Failure Treatment and Management | 2021-2025 | 210 | JP 8 | 97.47 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 534 | JP 25 | 96.46 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 421 | JP 18 | 96.62 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 602 | JP 35 | 95.89 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 353 | JP 10 | 96.05 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 486 | JP 22 | 93.85 |
| Nutrition and Health in Aging | 2021-2025 | 843 | JP 110 | 92.15 |
| Peripheral Artery Disease Management | 2021-2025 | 378 | JP 31 | 91.27 |
| Frailty in Older Adults | 2021-2025 | 662 | JP 72 | 90.52 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 504 | JP 31 | 90.78 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 901 | JP 53 | 81.97 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 361 | JP 23 | 72.78 |
| Potassium and Related Disorders | 2021-2025 | 346 | JP 27 | 74.37 |
| Lymphatic System and Diseases | 2021-2025 | 487 | JP 32 | 73.03 |
| Cardiac tumors and thrombi | 2021-2025 | 860 | JP 93 | 68.42 |
| Muscle and Compartmental Disorders | 2021-2025 | 664 | JP 54 | 54.73 |
| Vascular Anomalies and Treatments | 2021-2025 | 919 | JP 92 | 44.70 |
| Sympathectomy and Hyperhidrosis Treatments | 2021-2025 | 575 | JP 27 | 44.57 |